References
- Fuzery AK, Levin J, Chan MM, et al. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013;1:13
- Oliveira BM, Schmitt A, Fallkai P, et al. Is clinical proteomics heading towards to “bench to bedside”? Translational Proteomics 2013;1:53-6
- Skates SJ, Gillette MA, LaBaer J, et al. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res 2013;12:5383-94
- Oberg AL, Vitek O. Statistical design of quantitative mass spectrometry-based proteomic experiments. J Proteome Res 2009;5:2144-56
- Cairns DA. Statistical issues in quality control of proteomic analyses: good experimental design and planning. Proteomics 2011;6:1037-48
- Levin Y. The role of statistical power analysis in quantitative proteomics. Proteomics 2011;12:2565-7
- Oberg AL, Mahoney DW. Statistical methods for quantitative mass spectrometry proteomic experiments with labeling. BMC Bioinformatics 2012;13(Suppl 16):S7
- Wallstrom G, Anderson KS, LaBaer J. Biomarker discovery for heterogeneous diseases. Cancer Epidemiol Biomarkers Prev 2013;5:747-55
- Borrebaeck CA. Viewpoints in clinical proteomics: when will proteomics deliver clinically useful information? Proteomics Clin Appl 2012;7-8:343-5
- Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;20:1432-8
- Frantzi M, Bhat A, Latosinska A. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med 2014;1:7
- Ivanov AR, Colangelo CM, Dufresne CP, et al. Interlaboratory studies and initiatives developing standards for proteomics. Proteomics 2013;6:904-9
- Martinez-Bartolome S, Binz PA, Albar JP. The Minimal Information about a Proteomics Experiment (MIAPE) from the Proteomics Standards Initiative. Methods Mol Biol 2014;765-80
- Tabb DL. Quality assessment for clinical proteomics. Clin Biochem 2013;6:411-20
- Bereman MS. Tools for monitoring system suitability in LC MS/MS centric proteomic experiments. Proteomics 2015;15(5-6):891-902
- Paulovich AG, Billheimer D, Ham AJ, et al. Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol Cell Proteomics 2010;2:242-54
- Abbatiello SE, Schilling B, Mani DR, et al. Large-scale inter-laboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. Mol Cell Proteomics 2015, pii:mcp.M114.047050
- Chambers AG, Percy AJ, Simon R, et al. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum. Expert Rev Proteomics 2014;2:137-48
- Domon B, Gallien S. Recent advances in targeted proteomics for clinical applications. Proteomics Clin Appl 2015;9:423-31
- Grenache DG, Heichman KA, Werner TL, et al. Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass. Clin Chim Acta 2015;358-63